No Detail Found!

Effect of High-Intensity Atorvastatin on the Prevalence of No-Reflow Phenomenon in Patient Undergoing Primary PCI: A Cross-Sectional Study

Author(s)
MUHAMMAD SHAHAB-UD-DIN KHALIL FCPS Cardiology, FCPS-II Interventional Cardiology & Interventional Fellow at Hayatabad Medical Complex, Peshawar, Pakistan
MUHAMMAD ASGHAR KHAN Interventional Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan
ZEESHAN AFZAL Hayatabad Medical Complex, Peshawar, Pakistan
SALAH UDDIN King Zayed Hospital, Abu Zehbi, UAE
ABDUL LATIF FCPS-II Interventional Cardiology, Fellow in Interventional Cardiology Hayatabad Medical Complex, Peshawar, Pakistan
Abstract
Introduction: ST-segment elevation myocardial infarction (STEMI) is one of the most common heart problems worldwide. So far percutaneous coronary intervention (PCI) has proved to be the most successful method to restore blood flow after a STEMI attack. However, the breakdown of coronary plaques often results in a failed restoration of blood. The no-reflow phenomenon complicates the treatment and delays the patient's recovery. Statins have helped reduce cholesterol levels in the blood and have thus been used during primary PCI to enhance the chance of blood reflow. Atorvastatin is a promising candidate drug that reported promising results. Objective: In this study, the effect of high-intensity Atorvastatin has been assessed in preventing the no-reflow phenomenon. Study Design: Cross-sectional study Study Setting: Department of interventional Cardiology Hayatabad Medical Complex, Peshawar from 10-06-2022 to 10-102022. Material and Methods: A sample size of 149 was collected using non-probability consecutive sampling and was examined using Chi-Square for independence via the SPSS program. Results: The patients had several comorbidities, with hypertension being the most common. Over half of the patients were given atorvastatin, and over 97% of patients received balloon and stent procedures. 15% of patients experienced a no-reflow phenomenon, while 85% had a successful primary PCI. High-intensity atorvastatin was found to significantly reduce the risk of no-reflow (p < 0.001). Conclusion: The statistical outcome revealed that loading atorvastatin during the primary percutaneous coronary intervention (PCI) significantly reduces the risk of a no-reflow phenomenon.
Publication Details
Page(s) 566-568
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 17, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
atorvastatin, ST-segment elevation myocardial infarction (STEMI), No-Reflow Phenomenon, primary percutaneous coronary intervention (PCI)
0

Citations

0

Downloads

60

Views